Get the Stockscreener App
2.13
1.43%
0.03
Taysha Gene Therapies Inc stock is traded at $2.13, with a volume of 2.13M.
It is up +1.43% in the last 24 hours and up +77.50% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$2.10
Open:
$2.1
24h Volume:
2.13M
Relative Volume:
0.89
Market Cap:
$529.04M
Revenue:
$12.87M
Net Income/Loss:
$-114.34M
P/E Ratio:
-2.4636
EPS:
-0.8646
Net Cash Flow:
$-79.23M
1W Performance:
-17.44%
1M Performance:
+77.50%
6M Performance:
+42.00%
1Y Performance:
-15.81%
1-Day Range:
$2.06
$2.22
1-Week Range:
$1.845
$2.565
52-Week Range:
$1.05
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.13 | 529.04M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Wells Fargo & Company MN Has $179,000 Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Barclays PLC Grows Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Mariner LLC Has $101,000 Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 - The Manila Times
Taysha Gene Therapies to Release First Quarter 2025 - GlobeNewswire
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Taysha Gene Therapies Inc (NASDAQ: TSHA) Up 40.46% This Year: What To Expect Next - Stocksregister
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.3% – Should You Buy? - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Analysts - Defense World
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Taysha Gene Therapies (TSHA) Grants Employee Stock Option Under Inducement Plan | TSHA Stock News - GuruFocus
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Li - GuruFocus
BMO Capital Markets slashes price target on Taysha Gene Therapies Inc [TSHA] – find out why. - dbtnews.com
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Grants $108,450 Stock Option Package: New Executive Compensation Details Revealed - Stock Titan
Taysha Gene Therapies (TSHA) Gains Analyst Support with Promising Gene Therapy | TSHA Stock News - GuruFocus
Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - knoxdaily.com
Anchoring Your Portfolio: Is TSHA Stock a Safe Harbor? - investchronicle.com
60,000 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by LPL Financial LLC - Defense World
Gaining Ground: Taysha Gene Therapies Inc (TSHA) Closes Higher at 1.82, Up 1.11 - DWinneX
What is Taysha Gene Therapies Inc (TSHA) Stock Return on Shareholders’ Capital? - Sete News
Taysha Gene Therapies’ (TSHA) Overweight Rating Reaffirmed at Cantor Fitzgerald - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities - Defense World
Understanding the Risks of Investing in Taysha Gene Therapies Inc (TSHA) - knoxdaily.com
Examining TSHA’s book value per share for the latest quarter - uspostnews.com
Taysha Gene Therapies Inc (NASDAQ: TSHA) Prices Could Soar To Much Higher Levels In Coming Months - Marketing Sentinel
Geode Capital Management LLC Has $6.18 Million Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Keeping an Eye on Taysha Gene Therapies Inc (TSHA) After Insider Trading Activity - knoxdaily.com
Taysha Gene Therapies Inc [TSHA] stock Initiated by BMO Capital Markets analyst, price target now $5 - dbtnews.com
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
What is going on with Taysha Gene Therapies Inc? Sentiment Analysis - uspostnews.com
How Will Taysha Gene Therapies Inc (NASDAQ: TSHA) Perform In Months To Come? - Marketing Sentinel
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by JPMorgan Chase & Co. - Defense World
Vanguard Group Inc. Raises Stock Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity - Seeking Alpha
Wellington Management Group LLP Raises Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Commonwealth Equity Services LLC Purchases 31,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of “Buy” from Brokerages - The AM Reporter
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors - The Manila Times
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Target Price from Brokerages - Defense World
Taysha Expands Team: 822,000 Stock Options Awarded in Strategic Growth Move - Stock Titan
At $1.32 Price, Taysha Gene Therapies Inc (TSHA) Is Sitting And Waiting - stocksregister.com
Wall Street Was Disappointed By Taysha Gene Therapies Inc (NASDAQ: TSHA)’s -3.96% Stock Price Decline - Marketing Sentinel
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):